AbbVie (ABBV): $38.36 million was the positive money flow into the stock on Friday and the up/down ratio of ticks was also in favor of the bulls at 1.84. The value of trades done on upticks was $84.17 million, whereas, trades done on downticks were valued at $45.81 million. Money flows are calculated as the dollar value of composite uptick trades minus the dollar value of downtick trades. large traders, also sometimes called as the smart money, block traded $46.71 million worth stocks on upticks, which is a bullish indication. The downticks accounted only for $5.74 million worth of block trades showing a lack of interest among the large traders to sell the stock down. The up/down ratio of 8.13 was strongly in favor of the bulls. The money flow in block trades was $40.97 million. AbbVie (ABBV) fell $0.08 traded at $63.81, a change of -0.13% over the previous day. The stock is 0.77% for the week.
AbbVie (ABBV) has been rated by 13 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $90 and the lowest price target forecast is $47. The average forecast of all the analysts is $71.77 and the expected standard deviation is $10.83.
AbbVie (NYSE:ABBV): On Fridays trading session , Opening price of the stock was $64 with an intraday high of $64.09. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $63.575. However, the stock managed to close at $63.81, a loss of 0.13% for the day. On the previous day, the stock had closed at $63.89. The total traded volume of the day was 4,972,888 shares.
In a related news,The Officer (Executive Vice President) of AbbVie Inc., Schumacher Laura J sold 186,106 shares at $60.07 on June 24, 2016. The Insider selling transaction had a total value worth of $11,179,387. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
AbbVie Inc. (AbbVie) is a global, research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Companys products are focused on treating conditions, such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis and Crohns disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinsons disease; complications associated with chronic kidney disease and cystic fibrosis, and other health conditions, such as low testosterone. AbbVie also has a pipeline of new medicines, including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties, such as immunology, virology/liver disease, oncology, renal disease, neurological diseases and womens health. The Companys product portfolio includes HUMIRA, HCV products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products.